Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Study of TrEatment Discontinuations and Modifications for Patients With HER2+ and HER2-low Metastatic Breast Cancer On Trastuzumab Deruxtecan

NCT06386263 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06386263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06386263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Study of TrEatment Discontinuations and Modifications for Patients With HER2+ and HER2-low Metastatic Breast Cancer On Trastuzumab Deruxtecan
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
April 22, 2024
Completion date
July 7, 2025
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-low expressing breast cancer, her2-positive breast cancer, metastatic breast cancer, unresectable breast cancer